The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer.
Erkut Borazanci
No relevant relationships to disclose
Katy Schroeder
No relevant relationships to disclose
Gayle S. Jameson
No relevant relationships to disclose
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene